Clinical Trials

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04002947 2026-02-20

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

132 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-02-04

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04505254 2025-12-26

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05952024 2025-12-22

ACRUE

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06757647 2025-12-16

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

61 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04484012 2025-11-26

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

36 enrolled

Lymphoma, Mantle-Cell

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

79 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04941716 2025-11-19

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05388006 2025-10-14

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06846489 2025-06-03

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT05004064 2025-04-09

CARAMEL

48 enrolled

Lymphoma, Mantle-Cell

NCT04566887 2025-02-18

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

105 enrolled

Lymphoma, Mantle-Cell

NCT04626791 2024-03-12

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

45 enrolled

Lymphoma, Mantle-Cell

NCT03899337 2023-01-09

STELLAR

105 enrolled